# US 2025/0144255 A1 · Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144255 A1
- Document ID: US20250144255A1
- Status: Published application
- Kind: A1
- Application number: 18/713,445
- Filed: 2022-11-24
- Published: 2025-05-08
- Earliest claimed: 2021-11-25
- Applicants: Veraxa Biotech GmbH
- Inventors: Christine KÖHLER; Paul SAUTER
- Web page: https://patentgrep.com/patent/US20250144255A1

## CPC

- C07K 16/32: against translation products of oncogenes
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61K 51/103: {against receptors for growth factors or receptors for growth regulators}
- A61K 51/1045: {against animal or human tumor cells or tumor cell determinants}
- A61K 51/1096: {radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications}
- A61P 35/00: Antineoplastic agents
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- A61K 2121/00: Preparations for use in therapy
- A61K 2123/00: Preparations for testing in vivo
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel, site-specifically modified immunoglobulin molecules having the ability to bind to human epidermal growth factor receptor 2 (HER2) carrying in predetermined positions non-canonical amino acid residues (ncAAs); respective nucleic acid sequences encoding such modified immunoglobulin molecules; recombinant organisms useful for preparing such modified immunoglobulin molecules and adapted to express respective coding nucleic acid sequences; methods of preparing said site-specifically modified immunoglobulin molecules; conjugates formed between said site-specifically modified immunoglobulin molecules and a conjugation partner carrying a functional group reactive with said ncAA residues of the immunoglobulin molecule, and more particularly antibody-drug conjugates (ADCs). The invention also relates to specific conjugation partners and their preparation. The invention also relates to pharmaceutical compositions comprising such conjugates; as well as the use of such conjugates in medicine, in particular in the treatment of cancers overexpressing HER2.

## Claims

### Claim at position 1

1-39. (canceled)

### Claim 40

A site-selectively modified immunoglobulin molecule, comprising at least one immunoglobulin heavy chain (IgH) and at least one immunoglobulin light chain (IgL),
said IgH comprising a variable region VH encompassing
a CDR-H1 selected from SEQ ID NO: 9 and 10,
a CDR-H2 selected from SEQ ID NO: 11 and 12, and
a CDR-H3, selected from SEQ ID NO: 13 and 14, and a constant region CH; and
said IgL comprising a variable region VL encompassing
a CDR-L1 selected from SEQ ID NO: 15 and 16,
a CDR-L2 selected from SEQ ID NO: 17 and 18 and
a CDR-L3 selected from SEQ ID NO: 19 and 20; and
a constant region CL;
comprising
at least one side-selectively modified IgH; or
at least one side-selectively modified IgL; or
at least one side-selectively modified IgH and at least one side-selectively modified IgL;
wherein
said side-selectively modified immunoglobulin molecule has the ability to bind human epidermal growth factor receptor 2 (ERBB2 or HER2/neu);
said site-selectively modified immunoglobulin molecule is present in non-glycosylated, glycosylated or de-glycosylated form; and
said side-selectively modified immunoglobulin molecule comprises one site-selective modification in IgH and/or IgL, wherein said one site-selective modification is selected from
a site-selectively modified IgH comprising an ncAA in one amino acid
sequence position corresponding to a position selected from
a) VH positions: S25, P41, G42, K43, R50, D62, K65, E89, D102;
b) CH1 positions: E155, P156, S194, E219;
c) CH2 positions: K249, K251, E275, K277, D283, H288, K291, K293, E296, R304, K320, K323 and K343
each of SEQ ID NO: 2,
and/or
a site-selectively modified IgL comprising an ncAA in one amino acid sequence position corresponding to a position selected from
d) VL positions: G41, K42, K45, A51, P59, R61, D70, E81;
e) CL positions: A111, E143, D151, G157, K169, G200
each of SEQ ID NO: 4;
or
said side-selectively modified immunoglobulin molecule comprises two site-selective modifications, wherein said two site-selective modifications are selected from
double modifications in two amino acid sequence positions of at least one IgH corresponding to positions selected from:
a) CH1 positions: E155, P156, S194, E219;
b) CH2 positions: K249, K251, E275, K277, D283, H288, K291, K293, E296, R304, K320, K323 and K343
each of SEQ ID NO:2; or
double modifications of two amino acid sequence positions in at least one IgL corresponding to positions selected from:
c) CL positions: A111, E143, D151, G157, K169, G200 each of SEQ ID NO:4.

### Claim 41 (depends on 40)

The site-selectively modified immunoglobulin molecule of claim 40, which is an IgG1 molecule or an antigen binding fragment thereof.

### Claim 42 (depends on 40)

The site-selectively modified immunoglobulin molecule of claim 40, which is a monoclonal antibody or an antigen binding fragment thereof.

### Claim 43 (depends on 40)

The site-selectively modified immunoglobulin molecule of claim 40, which is a site-selectively modified TRASTUZUMAB mutant or an antigen binding fragment thereof, or a site-selectively modified PERTUZUMAB mutant or an antigen binding fragment thereof.

### Claim 44 (depends on 43)

The site-selectively modified immunoglobulin of claim 43, which is selected from the TRASTUZUMAB mutants selected from:
a) the IgH single mutants P41, G42, K249, K251, K291, K320 and K343 of SEQ ID NO:2 in each IgH;
b) the IgL single mutants G41, A51, P59, A111 and K169 of SEQ ID NO:4 in each IgL;
c) the IgH double mutants (K249/K320) and (K249/K343) of SEQ ID NO:2; in each IgH;
d) the (IgH/IgL) mixed double mutants (K249/K169), (K249/G41), (K320/K169), (K320/G41), and (P41/G41) of SEQ ID NO:2 and SEQ ID NO:4, respectively; in each IgH/IgL pair;
e) or an antigen binding fragment of anyone of a) to d); selected from
the IgH single mutants P41 and G42, of SEQ ID NO:2;
the IgL single mutants G41, A51 and P59 of SEQ ID NO:4, or
the (IgH/IgL) mixed double mutants (K249/G41), (K320/G41), and (P41/G41) of SEQ ID NO: 2 and SEQ ID NO:4, respectively.

### Claim 45 (depends on 43)

The site-selectively modified immunoglobulin of claim 43, which is selected from the TRASTUZUMAB mutants selected from single and double mutants in sequence positions of SEQ ID NO:2 and/or 4.

### Claim 46 (depends on 43)

The site-selectively modified immunoglobulin of claim 43, which is selected from the PERTUZUMAB mutants selected from:
a) the IgH single mutants P41, G42, K248, K250, K290, K319 and K342 of SEQ ID NO:6 in each IgH;
b) the IgL single mutants G41, A51, P59, A111 and K169 of SEQ ID NO:8 in each IgL;
c) the IgH double mutants (K248/K319) and (K248/K342) of SEQ ID NO:6 in each IgH;
d) the (IgH/IgL) mixed double mutants (K248/K169), (K248/G41), (K319/K169), (K319/G41), and (P41/G41) of SEQ ID NO:6 and SEQ ID NO:8, respectively; in each IgH/IgL pair;
e) or an antigen binding fragment of anyone of a) to d); selected from
the IgH single mutants P41 and G42 of SEQ ID NO:6
the IgL single mutants G41, A51, P59, A111 and K169 of SEQ ID NO:8 and
the (IgH/IgL) mixed double mutants (K248/G41), (K319/G41) and (P41/G41) of SEQ ID NO: 6 and SEQ ID NO:8, respectively.

### Claim 47 (depends on 40)

The site-selectively modified immunoglobulin of claim 40, wherein said ncAA carries a functional side chain wherein said functional side chain is capable of reaction via a Diels-Alder-type cycloaddition reaction is selected from
(i) a trans-cyclooctenyl dienophile group of the formula:
wherein
R1 is hydrogen, halogen, C1-C4-alkyl, (RaO)2P(O)O—C1-C4-alkyl, (RbO)2P(O)—C1-C4-alkyl, CF3, CN, hydroxyl, C1-C4-alkoxy, —O—CF3, C2-C5-alkenoxy, C2-C5-alkanoyloxy, C1-C4-alkylaminocarbonyloxy or C1-C4-alkylthio, C1-C4-alkylamino, Di-(C1-C4-alkyl)amino, C2-C5-alkenylamino, C2-C5-alkenyl-C1-C4-alkyl-amino or Di-(C2-C5-alkenyl)amino; and
Ra, Rb independently are hydrogen or C2-C5-alkanoyloxymethyl; or
(ii) a cyclooctynyl dienophile group of the formula:
wherein
R2 is hydrogen, halogen, C1-C4-alkyl, (RcO)2P(O)O—C1-C4-alkyl, (RdO)2P(O)—C1-C4-alkyl, CF3, CN, hydroxyl, C1-C4-alkoxy, —O—CF3, C2-C5-alkenoxy, C2-C5-alkanoyloxy, C1-C4-alkylaminocarbonyloxy or C1-C4-alkylthio, C1-C4-alkylamino, Di-(C1-C4-alkyl)amino, C2-C5-alkenylamino, C2-C5-alkenyl-C1-C4-alkyl-amino or Di-(C2-C5-alkenyl)amino; and
Rc, Rd independently are hydrogen or C2-C5-alkanoyloxymethyl.

### Claim 48 (depends on 47)

The site-selectively modified immunoglobulin of claim 47, wherein said ncAA is selected from SCO (2-amino-6-(cyclooct-2-yn-1-yloxycarbonylamino) hexanoic acid TCO-Lys (N—ε-((trans-Cyclooct-4-en-1-yloxy)carbonyl)-L-lysine), TCO*-Lys (N—ε-((trans-Cyclooct-2-en-1-yloxy)carbonyl)-L-lysine), TCO-Lys (N—ε-((trans-Cyclooct-3-en-1-yloxy)carbonyl)-L-lysine), TCO-E-Lys (N6-((((R,E)-cyclooct-4-en-1-yl)oxy) carbonyl)-L-lysine) and TCO*A-Lys (N6-((((S,E)-cyclooct-2-en-1-yl)oxy) carbonyl)-L-lysine).

### Claim 49 (depends on 40)

An antibody payload conjugate (APC), comprising at least one site-selectively modified immunoglobulin molecule of claim 40.

### Claim 50 (depends on 40)

A nucleic acid molecule comprising a nucleotide sequence encoding at least one site-selectively modified immunoglobulin polypeptide chain as defined in claim 40, and which comprises at least one codon allowing the incorporation of said ncAA into the encoded polypeptide sequence during protein expression.

### Claim 51 (depends on 40)

A method for preparing a side-selectively modified immunoglobulin molecule of claim 40, comprising one or more than one non-canonical amino acid residue (ncAAs), wherein the method comprises:
(a) providing the eukaryotic cell comprising:
(i) a pyrrolysyl tRNA synthetase,
(ii) a tRNA (tRNAPyl),
(iii) an ncAA or a salt thereof, and
(iv) a polynucleotide encoding the site-selectively modified immunoglobulin molecule, wherein any position of the site-selectively modified immunoglobulin molecule occupied by an ncAA residue is encoded by a codon that is the reverse complement of the anticodon comprised by the tRNAPyl, and
wherein the pyrrolysyl tRNA synthetase (i) is capable of acylating the tRNAPyl (ii) with the non-canonical amino acid or salt (iii); and
(b) allowing for translation of the polynucleotide (iv) by the eukaryotic cell, thereby producing the side-selectively modified immunoglobulin molecule.

### Claim 52 (depends on 51)

A method for preparing a polypeptide conjugate comprising:
(a) preparing a site-selectively modified immunoglobulin molecule comprising one or more than one ncAA residue using the method of claim 51 and
(b) reacting the site-selectively modified immunoglobulin molecule of step a) with one or more than one conjugation partner molecule such that the conjugation partner molecules bind covalently to the ncAA residue(s) of the site-selectively modified immunoglobulin molecule.

### Claim 53 (depends on 52)

The method of claim 52, wherein said conjugation partner carries at least one functional group, capable of reacting with said at least one ncAA side chain, contained in said site-selectively modified immunoglobulin molecule.

### Claim 54 (depends on 53)

The method of claim 53, wherein said at least one functional group comprises a 1,2,4,5-tetrazine moiety.

### Claim 55 (depends on 53)

The method of claim 53, wherein said conjugation partner comprises a payload molecule.

### Claim 56 (depends on 49)

A pharmaceutical composition comprising in a pharmaceutically acceptable carrier at least one APC as defined in claim 49.

### Claim 57 (depends on 49)

A method for diagnosing a patient as having a Her2 overexpressing tumor, comprising administering to the patient diagnostically effective amount of the antibody payload conjugate (APC) as defined in claim 49.

### Claim 58 (depends on 49)

A method for treating a patient having a Her2 overexpressing tumor, comprising administering to the patient a therapeutically effective amount of the antibody payload conjugate (APC) as defined in claim 49.

### Claim 59 (depends on 49)

The APC of claim 49, comprising at least one site-selectively modified immunoglobulin molecule, comprising at least one immunoglobulin heavy chain (IgH) and at least one immunoglobulin light chain (IgL),
said IgH comprising a variable region VH encompassing
a CDR-H1 according to SEQ ID NO: 9,
a CDR-H2 according to SEQ ID NO: 11, and
a CDR-H3, according to SEQ ID NO: 13, and a constant region CH; and
said IgL comprising a variable region VL encompassing
a CDR-L1 according to SEQ ID NO: 15,
a CDR-L2 according to SEQ ID NO: 17 and
a CDR-L3 according to SEQ ID NO: 19; and
a constant region CL;
wherein
at least one IgH is side-selectively modified by incorporation of one or two SCO residues within their amino acid sequence each in a sequence position which corresponds to a position selected from K249 and K320 according to SEQ ID NO: 2;
said side-selectively modified immunoglobulin molecule has the ability to bind human epidermal growth factor receptor 2 (ERBB2 or HER2/neu); and
each SCO is conjugated to a H-tetrazine-functionalized payload moiety P comprising a drug moiety D selected from auristatins and maytansinoids.

### Claim 60 (depends on 49)

The APC of claim 49 having the ability to bind human epidermal growth factor receptor 2 (ERBB2 or HER2/neu) and having the general formula (1)
wherein
n represents the number of the conjugated side chains, each chain comprising a payload moiety -L-D;
wherein
D is selected from auristatins and maytansinoids, and
L is an optionally cleavable linker moiety,
A represents a site-selectively modified immunoglobulin molecule, comprising at least one immunoglobulin heavy chain (IgH) and at least one immunoglobulin light chain (IgL),
wherein
said IgH comprising a variable region VH encompassing
a CDR-H1 according to SEQ ID NO: 9,
a CDR-H2 according to SEQ ID NO: 11, and
a CDR-H3, according to SEQ ID NO: 13, and a constant region CH; and
said IgL comprising a variable region VL encompassing
a CDR-L1 according to SEQ ID NO: 15,
a CDR-L2 according to SEQ ID NO: 17 and
a CDR-L3 according to SEQ ID NO: 19; and
a constant region CL;
and
at least one IgH is side-selectively conjugated with said payload moiety -L-D in one or two sequence positions each corresponding to a position selected from K249 and K320 according to SEQ ID NO:2
in any stereoisomeric and/or regioisomeric form or as mixture of at least two different stereoisomers and regioisomers thereof, as well as either in non-glycosylated, glycosylated or de-glycosylated form.

### Claim 61 (depends on 60)

A method of preparing the APC of the general formula 1 of claim 60,
in any stereoisomeric and/or regioisomeric form or as mixture of at least two different stereoisomers and regioisomers thereof, as well as either in non-glycosylated, glycosylated or de-glycosylated form;
which method comprises reacting a SCO-functionalized immunoglobulin molecule of the general formula 2
and a H-tetrazine functionalized payload molecule of the general formula 3
in order to obtain an APC of the general formula (1) and optionally isolating said product.

### Claim 62 (depends on 60)

A pharmaceutical composition comprising in a pharmaceutically acceptable carrier at least an APC as defied in claim 60.

### Claim 63 (depends on 60)

A method for diagnosing or treating a patient having breast cancer, comprising administering to the patient diagnostically or therapeutically effective amount of the antibody payload conjugate (APC) as defined in claim 60.

### Claim 64 (depends on 49)

The APC of claim 49, side-selectively conjugated with at least one payload moiety comprising a moiety -L-P of Formula 4.1:
wherein
m is an integer from 1 to 8 and
M is a radioactive metal isotope selected from 111-Indium, 64-Copper, 67-Copper, 227-Thorium, 188-Rhenium, 177-Lutetium, 89-Zirkonium, 68-Gallium, 99m-Technetium, 225-Actinium, 213-Bismut, 90-Ytrium and 212-Plumbum.

### Claim 65 (depends on 64)

The APC of claim 64, wherein at least one IgH is side-selectively conjugated with said payload moiety -L-P in one sequence position corresponding to position A121 according to SEQ ID NO:2.

### Claim 66 (depends on 65)

The APC of claim 65, wherein at least one IgH is side-selectively modified by incorporation of an TCO*A within their amino acid sequence in a sequence position which corresponds to a position A121 according to SEQ ID NO:2;
said side-selectively modified immunoglobulin molecule has the ability to bind human epidermal growth factor receptor 2 (ERBB2 or HER2/neu);
and
at least one TCO*A is conjugated to a H-tetrazine-functionalized payload moiety -L-P.

### Claim 67 (depends on 66)

The APC of claim 66, wherein the H-tetrazine-functionalized payload moiety -L-P is of the formula 5:
wherein
m is an integer from 1 to 8 and
M is a radioactive metal isotope selected from 111-Indium, 64-Copper, 67-Copper, 227-Thorium, 188-Rhenium, 177-Lutetium, 89-Zirkonium, 68-Gallium, 99m-Technetium, 225-Actinium, 213-Bismut, 90-Ytrium and 212-Plumbum.

### Claim 68 (depends on 64)

A method for diagnosing or treating a patient having breast cancer, comprising administering to the patient a diagnostically or therapeutically effective amount of the antibody payload conjugate (APC) as defined in claim 64.
